Curevac

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:1000 publications

Grant number: N/A

Grant search

Key facts

  • Disease

    COVID-19
  • Known Financial Commitments (USD)

    $15,300,000
  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)
  • Principal Investigator

    Pending
  • Research Location

    Germany
  • Lead Research Institution

    Curevac
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

mRNA Full Length S stabilized (unmodified and codon optimized) Phase I safety and immunogenicity

Publicationslinked via Europe PMC

Disordered regions in the IRE1α ER lumenal domain mediate its stress-induced clustering.

Inherited human RelB deficiency impairs innate and adaptive immunity to infection.

Sex-specific high-sensitivity troponin T cut-points have similar safety but lower efficacy than overall cut-points in a multisite U.S. cohort.

Innate immune sensing of cell death in disease and therapeutics.

Exploring the feasibility and acceptability of community paramedicine programs in achieving vaccination equity: a qualitative study.

Recruitment of CXCR4+ type 1 innate lymphoid cells distinguishes sarcoidosis from other skin granulomatous diseases.

Integrating nutrition and culinary medicine into preclinical medical training.

Effectiveness of a nurse-led family empowerment program to improve the quality of life among pregnant adolescents: A randomized controlled trial.

SOX-5 Transcription Factor: a Novel Psoriatic Autoantigen Preferentially Found in Women.